Cagrilintide: Molecular Structure

Molecular Structure#

Cagrilintide is a synthetic analog of human amylin (islet amyloid polypeptide, IAPP), a 37-amino acid peptide hormone normally produced by pancreatic beta cells. The molecular design of cagrilintide addresses two fundamental limitations of native amylin: its rapid metabolic degradation (plasma half-life of approximately 13 minutes) and its intrinsic tendency to aggregate into amyloid fibrils, which limits both pharmaceutical stability and therapeutic utility.

The molecular engineering strategy employed in cagrilintide involves two complementary approaches. First, strategic amino acid substitutions within the peptide backbone prevent amyloid fibrillation while maintaining receptor binding activity. Second, acylation with a fatty acid side chain enables non-covalent binding to serum albumin, dramatically extending the circulating half-life to approximately 7 days and permitting once-weekly dosing.

Amino Acid Modifications#

Human amylin has the sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY with a disulfide bridge between Cys2 and Cys7. The amyloidogenic region of amylin is located primarily within residues 20 to 29 (the sequence SNNFGAILSS), which adopts beta-sheet conformations that template further aggregation.

Cagrilintide incorporates amino acid substitutions derived from pramlintide (a previously approved amylin analog) and additional modifications. Pramlintide introduced three proline substitutions at positions 25, 28, and 29 (A25P, S28P, S29P) based on the observation that rat amylin, which contains prolines at these positions, does not form amyloid fibrils. Proline residues disrupt beta-sheet formation due to their cyclic structure and inability to act as hydrogen bond donors.

Cagrilintide retains these anti-aggregation modifications and includes additional substitutions optimized for receptor potency and metabolic stability. The specific modifications enhance binding affinity at the AMY1 and AMY3 receptor subtypes while maintaining the anti-fibrillation properties necessary for pharmaceutical stability. The Cys2-Cys7 disulfide bridge, which is critical for receptor binding, is preserved.

Acylation Strategy and Albumin Binding#

The defining structural feature that distinguishes cagrilintide from earlier amylin analogs (such as pramlintide) is the attachment of a C18 fatty diacid (octadecanedioic acid) side chain. This acylation strategy is conceptually identical to the approach used in semaglutide (where a C18 fatty diacid extends the half-life of a GLP-1 analog) and was pioneered by Novo Nordisk across multiple peptide programs.

The fatty acid is attached to a lysine residue in the peptide chain through a linker that includes glutamic acid spacers and a mini-polyethylene glycol (mini-PEG) element. This linker design optimizes the spatial presentation of the fatty acid for albumin binding while minimizing interference with receptor interactions.

In the circulation, the C18 fatty diacid side chain binds non-covalently to the fatty acid binding sites on serum albumin (primarily Sudlow site II). Albumin is an abundant plasma protein (approximately 35 to 50 grams per liter) with a circulating half-life of approximately 19 days. By binding to albumin, cagrilintide effectively adopts the pharmacokinetic profile of this large carrier protein, resulting in dramatically slowed renal clearance and proteolytic degradation.

The albumin binding is reversible, with a dynamic equilibrium between bound and free forms. Only the free (unbound) form can interact with amylin receptors and be cleared from the circulation. This equilibrium creates a depot effect where the albumin-bound fraction serves as a reservoir, maintaining steady-state plasma concentrations of active peptide throughout the weekly dosing interval.

Comparison with Pramlintide#

Pramlintide (Symlin) is the only previously approved amylin analog. The structural comparison between pramlintide and cagrilintide highlights the advances in peptide engineering. Pramlintide contains the three proline substitutions that prevent aggregation but is otherwise unmodified. Its half-life is approximately 48 minutes, requiring injection before each meal (typically 3 times daily). Pramlintide was approved for use as an adjunct to insulin therapy in diabetes, not for obesity treatment.

Cagrilintide represents a next-generation approach with the addition of the acylation technology, transforming the pharmacokinetic profile from multiple daily injections to once-weekly administration. The additional amino acid modifications in cagrilintide also provide enhanced receptor potency compared to pramlintide, meaning that lower molar doses can achieve equivalent or greater pharmacological effects.

Receptor Pharmacology#

Cagrilintide demonstrates potent agonist activity at the AMY1 receptor (CTR plus RAMP1), AMY3 receptor (CTR plus RAMP3), and the calcitonin receptor (CTR). The relative activity at these receptor subtypes differs from native amylin, with cagrilintide showing enhanced activity at certain subtypes that are believed to be most relevant for appetite suppression.

The amylin receptor subtypes are expressed at high levels in the area postrema and nucleus of the solitary tract, brain regions that are critical for the integration of peripheral satiety signals. The blood-brain barrier is fenestrated in these regions, allowing circulating cagrilintide to access central amylin receptors. The long circulating half-life ensures sustained receptor activation throughout the weekly dosing interval, producing continuous appetite suppression rather than the meal-time-limited effects of pramlintide.

Physicochemical Properties#

The molecular weight of cagrilintide is approximately 4030 daltons, reflecting the peptide backbone plus the acyl side chain with its linker. The compound is formulated as a solution for subcutaneous injection, unlike many research peptides that require reconstitution from lyophilized powder. The acylation improves the solubility and pharmaceutical stability of the formulation compared to unmodified amylin analogs.

The pharmaceutical formulation used in clinical trials is a clear, colorless to slightly yellow solution in a prefilled pen device. The formulation pH, buffer composition, and excipients are optimized for subcutaneous bioavailability and injection site tolerability.

Stability Characteristics#

The combination of anti-aggregation amino acid substitutions and the acyl side chain provides cagrilintide with substantially improved stability compared to native amylin. The proline substitutions prevent the beta-sheet aggregation that causes native amylin to form fibrils within hours in solution. The acylation may provide additional steric protection against proteolytic degradation.

In the clinical formulation, cagrilintide is stable as a ready-to-use solution, eliminating the reconstitution step required for lyophilized peptides. This represents a significant practical advantage for clinical use, reducing preparation errors and improving convenience. Storage is at refrigerated temperatures (2 to 8 degrees Celsius), with defined stability at room temperature for limited periods during use.

Related Reading#

• Cagrilintide overview and research guide
• Peptides similar to Cagrilintide
• Cagrilintide research evidence